• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于资源有限国家B细胞淋巴瘤诊断及在转诊至专科中心前对病例进行分流的免疫组织化学最佳最小检测组合

Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers.

作者信息

Disanto Maria Giulia, Ambrosio Maria Raffaella, Rocca Bruno Jim, Ibrahim Hazem A H, Leoncini Lorenzo, Naresh Kikkeri N

机构信息

From the Department of Histopathology, Imperial College Healthcare NHS Trust & Imperial College, London, United Kingdom.

Department of Medical Biotechnologies, Section of Pathology, University of Siena, Siena, Italy.

出版信息

Am J Clin Pathol. 2016 May;145(5):687-95. doi: 10.1093/ajcp/aqw060.

DOI:10.1093/ajcp/aqw060
PMID:27247372
Abstract

OBJECTIVES

Establish and validate optimal minimal immunohistochemistry panels for usage in a staged algorithmic manner for precise diagnosis of B-cell lymphomas in countries with limited resources. Suggest short panels of immunostains to be used in referring units that refer suspected lymphomas to specialist diagnostic centers in resourceful countries.

METHODS

Significant proportion of six B-cell lymphomas has characteristic morphology requiring a short panel of confirmatory immunostains. The rest would go through five different algorithms.

RESULTS

812 cases in which a B-cell lymphoma or an HIV-associated lymphoma was suspected on morphological grounds were evaluated. This led to arriving at a specific diagnosis of 799 B-cell lymphomas. A correct diagnosis was achievable in 69% cases with the application of three to five antibodies; others required additional work-up.

CONCLUSIONS

The panels/algorithms assist pathologists in practicing lymphoma diagnostics in countries with limited resources and in making lymphoma referrals to specialist centers.

摘要

目的

建立并验证最佳的最小免疫组织化学检测组合,以便在资源有限的国家以分阶段算法方式用于精确诊断B细胞淋巴瘤。建议在将疑似淋巴瘤转诊至资源丰富国家的专科诊断中心的转诊单位中使用简短的免疫染色检测组合。

方法

六种B细胞淋巴瘤中有很大一部分具有特征性形态,需要一组简短的确认性免疫染色。其余的将通过五种不同的算法进行分析。

结果

对812例因形态学原因怀疑为B细胞淋巴瘤或HIV相关淋巴瘤的病例进行了评估。这导致对799例B细胞淋巴瘤做出了明确诊断。应用三到五种抗体可在69%的病例中实现正确诊断;其他病例则需要进一步检查。

结论

这些检测组合/算法有助于资源有限国家的病理学家进行淋巴瘤诊断,并将淋巴瘤转诊至专科中心。

相似文献

1
Optimal Minimal Panels of Immunohistochemistry for Diagnosis of B-Cell Lymphoma for Application in Countries With Limited Resources and for Triaging Cases Before Referral to Specialist Centers.用于资源有限国家B细胞淋巴瘤诊断及在转诊至专科中心前对病例进行分流的免疫组织化学最佳最小检测组合
Am J Clin Pathol. 2016 May;145(5):687-95. doi: 10.1093/ajcp/aqw060.
2
Diagnostic Algorithm of Common Mature B-Cell Lymphomas by Immunohistochemistry.免疫组织化学法诊断常见成熟B细胞淋巴瘤的算法
Arch Pathol Lab Med. 2017 Sep;141(9):1236-1246. doi: 10.5858/arpa.2016-0521-RA. Epub 2017 Jun 13.
3
An algorithmic approach to diagnose haematolymphoid neoplasms in effusion by combining morphology, immunohistochemistry and molecular cytogenetics.一种通过结合形态学、免疫组织化学和分子细胞遗传学来诊断积液中血液淋巴系统肿瘤的算法方法。
Cytopathology. 2018 Feb;29(1):10-21. doi: 10.1111/cyt.12449. Epub 2017 Sep 15.
4
Application of Immunophenotyping and Heteroduplex Polymerase Chain Reaction (hPARR) for Diagnosis of Canine Lymphomas.免疫表型分析和异源双链聚合酶链反应(hPARR)在犬淋巴瘤诊断中的应用
Asian Pac J Cancer Prev. 2016;17(6):2909-16.
5
Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas.免疫组织化学的实际应用:弥漫性大B细胞淋巴瘤及相关大B细胞淋巴瘤的评估
Arch Pathol Lab Med. 2015 Sep;139(9):1094-107. doi: 10.5858/arpa.2014-0451-CP. Epub 2015 Jan 2.
6
New immunohistochemistry for B-cell lymphoma and Hodgkin lymphoma.用于B细胞淋巴瘤和霍奇金淋巴瘤的新型免疫组织化学技术。
Arch Pathol Lab Med. 2014 Dec;138(12):1666-72. doi: 10.5858/arpa.2014-0058-RA.
7
Diagnosis of Burkitt lymphoma using an algorithmic approach--applicable in both resource-poor and resource-rich countries.使用算法方法诊断伯基特淋巴瘤——适用于资源匮乏和资源丰富的国家。
Br J Haematol. 2011 Sep;154(6):770-6. doi: 10.1111/j.1365-2141.2011.08771.x. Epub 2011 Jul 1.
8
Oct2 and Bob1 are sensitive and specific markers in lineage determination of B cell lymphomas with no expression of conventional B cell markers.Oct2和Bob1是B细胞淋巴瘤谱系确定中的敏感且特异的标志物,这些淋巴瘤不表达传统B细胞标志物。
Histopathology. 2016 Nov;69(5):775-783. doi: 10.1111/his.13017. Epub 2016 Aug 5.
9
Polyclonal antibody targeting SOX11 cannot differentiate mantle cell lymphoma from B-cell non-Hodgkin lymphomas.针对 SOX11 的多克隆抗体无法区分套细胞淋巴瘤与 B 细胞非霍奇金淋巴瘤。
Am J Clin Pathol. 2013 Dec;140(6):795-800. doi: 10.1309/AJCPEBOUJ7GVYVLG.
10
Report of an International Network of Cancer Treatment and Research workshop on non-Hodgkin's lymphoma in developing countries.发展中国家非霍奇金淋巴瘤国际癌症治疗与研究网络研讨会报告。
Blood Cells Mol Dis. 2004 Nov-Dec;33(3):330-7. doi: 10.1016/j.bcmd.2004.08.001.

引用本文的文献

1
Diffuse large B cell lymphoma (DLBCL): epidemiology, pathophysiology, risk stratification, advancement in diagnostic approaches and prospects: narrative review.弥漫性大B细胞淋巴瘤(DLBCL):流行病学、病理生理学、风险分层、诊断方法进展及前景:叙述性综述
Discov Oncol. 2025 Feb 15;16(1):184. doi: 10.1007/s12672-025-01958-w.
2
Standardization of Manual Method of Immunohistochemical Staining for Breast Cancer Biomarkers at Tertiary Cancer Care Center: An Audit.三级癌症护理中心乳腺癌生物标志物免疫组织化学染色手工方法的标准化:一项审计
Cureus. 2022 Jun 8;14(6):e25773. doi: 10.7759/cureus.25773. eCollection 2022 Jun.
3
Molecular Diagnostic Review of Diffuse Large B-Cell Lymphoma and Its Tumor Microenvironment.
弥漫性大B细胞淋巴瘤及其肿瘤微环境的分子诊断综述
Diagnostics (Basel). 2022 Apr 27;12(5):1087. doi: 10.3390/diagnostics12051087.
4
Diagnosis and Management of Diffuse Large B-Cell Lymphoma: Society of Medical Oncology, Pakistan Society of Hematology, and Pakistan Society of Clinical Oncology Joint Clinical Practice Guideline.弥漫性大 B 细胞淋巴瘤的诊断与治疗:医学肿瘤学会、巴基斯坦血液病学会和巴基斯坦临床肿瘤学会联合临床实践指南。
JCO Glob Oncol. 2021 Sep;7:1647-1658. doi: 10.1200/GO.21.00320.
5
Distinct pattern of lymphoid neoplasms characterizations according to the WHO classification (2016) and prevalence of associated Epstein-Barr virus infection in Nigeria population.根据世界卫生组织(2016年)分类法对淋巴瘤的不同特征模式以及尼日利亚人群中相关爱泼斯坦-巴尔病毒感染的患病率。
Infect Agent Cancer. 2021 May 24;16(1):36. doi: 10.1186/s13027-021-00378-z.
6
Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2.B细胞和T细胞淋巴瘤及白血病中的点突变特异性抗体:靶向异柠檬酸脱氢酶2(IDH2)、KRAS、BRAF以及其他生物标志物RHOA、干扰素调节因子8(IRF8)、髓样分化因子88(MYD88)、ID3、NRAS、剪接因子3B亚基1(SF3B1)和EZH2
Diagnostics (Basel). 2021 Mar 27;11(4):600. doi: 10.3390/diagnostics11040600.